Vanda Pharmaceuticals, Inc. (VNDA) Posts Wider than Expected Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall St headed for weekly gains as earnings season nears
- Oil falls as Trump comments on Iran talks ease supply fears
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $4.57 +0.88%
Revenue Growth %: +23.2%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
HOVR, VFS, PGR, More
Revenue Growth %: +23.2%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
HOVR, VFS, PGR, More
Join SI Premium – FREE
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q3 EPS of ($0.11), $0.03 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $8 million versus the consensus estimate of $8.26 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
- Lg Energy 3q Oper Profit 756.0b Won, Est. 365.48b Won - Bloomberg
- Helen of Troy (HELE) Tops Q2 EPS by 28c, Misses on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
